FDA Approves FASENRA — AstraZeneca Pharmaceuticals LP

AstraZeneca announced on November 14, 2017, that the FDA granted full approval for its blockbuster respiratory drug FASENRA, the subcutaneous formulation of benralizumab. This approval solidifies the company’s position in the competitive asthma market by offering a durable therapeutic alternative to rival biologics within its respiratory franchise.